Raqualia Pharma Incorporated operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Raqualia Pharma Incorporated with three other
companies in this sector in Japan:
Carna Biosciences Inc
sales of 811.60 million Japanese Yen [US$7.18 million]
of which 88%
was Drug Discovery Support Business),
Human Metabolome Technologies Inc
(780.38 million Japanese Yen [US$6.91 million]
of which 90%
was Metabolome analysis business), and
BrightPath Biotherapeutics Co Ltd
(822.56 million Japanese Yen [US$7.28 million]
of which 100%
was Commerical Physical Research).
Sales increased substantially in 2016:
During the year ended December of 2016, sales at
Raqualia Pharma Incorporated were ¥705.24 million (US$6.24 million).
increase of 384.7%
versus 2015, when the company's sales were ¥145.50 million.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Raqualia Pharma Incorporated had sales
of ¥684.20 million.